Pfizer’s vaccine is most in-demand

Data from SurveyMonkey and Outbreaks Near Me

Hello from SurveyMonkey!

The pause on distribution of the Johnson and Johnson COVID-19 vaccine may be over, but Americans’ willingness to receive that particular vaccination brand has still not fully recovered. New tracking data from SurveyMonkey and Outbreaks Near Me, a team of epidemiologists at Boston Children’s Hospital and the Harvard School of Medicine, provides an update on our earlier data showing that demand for the Pfizer and Moderna vaccines has held steady or even increased in recent days, while demand for Johnson & Johnson is well below where it was a month ago.

Just 23% of those who have not yet been vaccinated now say they would be willing to receive the Johnson and Johnson vaccine, up slightly from 17% on April 19 but still well below its level prior to the pause. Pfizer and Moderna, on the other hand, are both seeing slightly increased demand since the pause on Johnson & Johnson distribution was announced on April 13. 

With more than half of adults in the U.S. already having been at least partially vaccinated, a greater and greater proportion of the people remaining to be vaccinated are those who say they are hesitant to get a shot. The chart below subsets out willingness to receive each vaccine just among those who have always said they are eager to get vaccinated. The percent willing to receive the Johnson & Johnson vaccine among this group plummeted from 47% on April 12 to 19% on April 19, but has since risen to 31% by May 2 and seems to be on an upward trajectory. 

There’s further differentiation within this group: 40% of men but just 18% of women now say they would be willing to get the Johnson & Johnson vaccine. Before the pause, men and women were about equally likely to say they would take Johnson & Johnson. 

Among those who have not yet been vaccinated and are “not sure” whether they want to get vaccinated, demand for all the vaccines--including Johnson & Johnson--is even lower. Just 18% of people in this group now say they would be willing to receive the Johnson & Johnson vaccine, down from 28% on April 12, and on a trajectory that has plateaued since the pause was announced. For comparison, 36% of people in this group say they would be willing to receive the Pfizer vaccine and 27% would be willing to get the Moderna vaccine—both several points higher than their baseline before the Johnson & Johnson pause.

For more on this data, or to find results by age, race, income, or partisanship, check out our latest Tableau dashboard. We’ll update this with new data every Monday. 

That’s all for this update! Thanks for reading and following along with us.